An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

NCT06129812 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1132

Last updated 2023-11-13

No results posted yet for this study

Summary

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Conditions

Interventions

DRUG

Neoadjuvant treatment

Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2021-12-31
Completion
2021-12-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06129812 on ClinicalTrials.gov